

Univ.-Prof. Dr. med Georg Heß
Department of Hematology, Oncology and Pneumology
University Medical School of the
Johannes Gutenberg-University
Langenbeckstr. 1
55101 Mainz
Germany

Tel.: 0049-(0)6131-17-5040
Fax: 0049-(0)6131-17-6678
E-mail: georg.hess@unimedizin-mainz.de

CURRICULUM VITAE

General Data

* 11.12.1966

University education

- Medicine - Mainz, New York, Idar-Oberstein, 1988-1994
- Thesis, 1996
- "Habilitation" - Venia legendi, 2007

Medical education

- 1994-2002: III. Department of Internal Medicine, Johannes Gutenberg-University, Mainz
- Specialty Internal Medicine, 2001
- Specialty Hematology/Oncology, 2002

Current position

- Head: Clinical Research Board of the UMM since 2017
- Full Professor of Medicine, Clinical experimental hematology and oncology since 2016
- Speaker: Working Party clinical trials of the UCT Mainz (CCC) since 2015
- Head of Study Department Hematology and Oncology since 07/2008
- Head Residency Program Hematology/Oncology since 2005
- Attending Physician III. Med. Department since 10/2003
- Lecturer: Key lectures internal medicine – lymphoma and multiple myeloma, Joined lectures: pathology/hematology

Memberships, Cooperative Boards and Board positions

- Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO), since 1998
- Subcommittee on Clinical Research, Auditor (DGHO), since 2015
- European Haematology Association (EHA), since 2005
- German Lymphoma Alliance (GLA), Board Member 2016-2019
- GLA - Working Party Mantle Cell Lymphoma, Speaker since 2019
- GLA - Working Party Early Trials, Speaker 2016-2019
- Prior Study Group activity (now all within GLA): GLSG, DSHNHL, ETN, since 1998

Clinical Trials

- „Prüfarzt für klinische Studien“(Clinical research scientist) since 1999, re-education 2019
- Continuous Education „Good Clinical Praxis“ since 1999
- Study Design of past and current investigator initiated clinical trials
- Leiter Klinische Prüfung (Coordinating principal investigator Germany), Principal Investigator or Subinvestigator in more than 100 clinical trials from phase I-IV since 1998

Current research projects

- Investigator initiated trials: GOAL-I (DLBCL), VIRAL (MCL), GOAL-II (DLBCL), EMCL-CAR-1 (MCL, activation)
- European Mantle Cell Lymphoma Registry, Coordinator, Sponsoring institution
- German Lymphoma Alliance-Registry, named Coordinator for pan-lymphoma registry
- Survivorship research, improved consenting in oncologic patients.

Lab based work

- Head of Molecular Diagnostics Lab, III. Med. Klinik 1996-2010
- MRD – Immune reconstitution after B-cell depleting therapies, Tumor Vaccination Center, 1999-2004
- Central Diagnostics Lab of CML trials 1998-2002

Reviewer for (sel)

- The Lancet, The Lancet Oncology, Haematologica, Leukemia, European Journal of Hematology, Leukemia and Lymphoma, Br. J. of Cancer, Annals of Hematology, Hematological Oncology, British Journal of Hematology, Bone Marrow Transplantation

Publications (sel)

- Knop S, Engelhardt M, Liebisch P, et al: Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. *Leukemia* 33:2710-2719, 2019
- Furstenau M, Bahlo J, Fink AM, et al: Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. *Leukemia*, 2019
- Rule S, Jurczak W, Jerkeman M, et al: Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. *Leukemia* 32:1799-1803, 2018
- Gopal AK, Schuster SJ, Fowler NH, et al: Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. *J Clin Oncol* 36:2405-2412, 2018
- Jurczak W, Ramanathan S, Giri P, et al: Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. *Leuk Lymphoma*:1-9, 2017
- Fritsch K, Kasenda B, Schorb E, et al: High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). *Leukemia* 31:846-852, 2017
- Einsele H, Engelhardt M, Tapprich C, et al: Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. *Br J Haematol*, 2017
- Viardot A, Goebeler ME, Hess G, et al: Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. *Blood* 127:1410-6, 2016
- Goebeler ME, Knop S, Viardot A, et al: Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. *J Clin Oncol* 34:1104-11, 2016
- O'Connor OA, Horwitz S, Masszi T, et al: Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. *Journal of Clinical Oncology*, 2015
- Kirschey S, Flohr T, Wolf HH, et al: Rituximab combined with DEXA-BEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. *Br J Haematol* 168:824-34, 2015
- Scholz CW, Pinto A, Linkesch W, et al: (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. *J Clin Oncol* 31:308-13, 2013
- Fayad L, Offner F, Smith MR, et al: Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin with Rituximab. *J Clin Oncol* 31:573-83, 2013
- Hess G: New combinations for mantle cell lymphoma: concerted action needed. *Lancet Oncol* 12:315-6, 2011
- Dreyling M, Kluijn-Nelemans HC, Bea S, et al: Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. *Leuk Lymphoma*, 2011
- Stolz C, Hess G, Hahnel PS, et al: Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. *Blood* 112:3312-21, 2008
- Morschhauser F, Illidge T, Huglo D, et al: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. *Blood* 110:54-8, 2007
- Hess G, Bunjes D, Siegert W, et al: Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. *J Clin Oncol* 23:7583-93, 2005
- Hess G, Flohr T, Huber C, et al: Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. *Bone Marrow Transplant* 31:775-82, 2003